Teachers Retirement System of The State of Kentucky Reduces Stake in Lantheus Holdings, Inc. $LNTH

Teachers Retirement System of The State of Kentucky cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 49.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,321 shares of the medical equipment provider’s stock after selling 19,494 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Lantheus were worth $1,042,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of LNTH. Assenagon Asset Management S.A. bought a new position in shares of Lantheus during the 3rd quarter valued at approximately $65,654,000. Polaris Capital Management LLC purchased a new stake in Lantheus during the 3rd quarter valued at $32,687,000. Norges Bank bought a new stake in Lantheus in the second quarter worth $32,631,000. William Blair Investment Management LLC lifted its position in Lantheus by 46.7% in the third quarter. William Blair Investment Management LLC now owns 574,681 shares of the medical equipment provider’s stock worth $29,475,000 after buying an additional 183,059 shares during the last quarter. Finally, TD Asset Management Inc boosted its stake in Lantheus by 25.0% during the third quarter. TD Asset Management Inc now owns 790,950 shares of the medical equipment provider’s stock worth $40,568,000 after buying an additional 158,358 shares during the period. 99.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on LNTH shares. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. William Blair upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday, February 26th. Citizens Jmp increased their price objective on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research report on Tuesday, February 24th. Finally, Truist Financial raised their price objective on shares of Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $82.17.

Lantheus Stock Down 4.9%

Shares of LNTH opened at $72.56 on Friday. The firm has a market capitalization of $4.69 billion, a P/E ratio of 21.53 and a beta of -0.11. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. The firm has a fifty day moving average price of $69.11 and a 200-day moving average price of $60.90.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping the consensus estimate of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company had revenue of $406.79 million for the quarter, compared to the consensus estimate of $367.03 million. During the same quarter last year, the firm posted $1.59 EPS. The firm’s revenue was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.